LYNOZYFIC 200 mg/10mL
linvoseltamab-gcpt · INJECTION, SOLUTION, CONCENTRATE · Regeneron Pharmaceuticals, Inc.
LYNOZYFIC is a injection, solution, concentrate containing linvoseltamab-gcpt at 200 mg/10mL, taken intravenous. Manufactured by Regeneron Pharmaceuticals, Inc..
Key Facts
- Brand Name
- LYNOZYFIC
- Generic Name
- linvoseltamab-gcpt
- NDC Code (Product)
61755-056- Manufacturer
- Regeneron Pharmaceuticals, Inc.
- Strength
- 200 mg/10mL
- Dosage Form
- INJECTION, SOLUTION, CONCENTRATE
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761400
- Drug Class
- Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager [EPC]
- Marketing Start
- 07/02/2025
Recall History
No Recall HistoryFrequently Asked Questions
What is LYNOZYFIC used for?
LYNOZYFIC contains linvoseltamab-gcpt. It is a injection, solution, concentrate taken intravenous. Consult your doctor for specific uses.
Is LYNOZYFIC a controlled substance?
LYNOZYFIC is not classified as a controlled substance by the DEA.
What is the generic name for LYNOZYFIC?
The generic name for LYNOZYFIC is linvoseltamab-gcpt. There are no other listed brand versions of linvoseltamab-gcpt.
What is the NDC code for LYNOZYFIC 200 mg/10mL?
The NDC (National Drug Code) for LYNOZYFIC 200 mg/10mL is 61755-056, listed by Regeneron Pharmaceuticals, Inc..
Other LYNOZYFIC Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)